HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Rapidly Growing Prestige Brands Still Positioned For OTC Pickups

This article was originally published in The Tan Sheet

Executive Summary

The company says it successfully integrated the OTC portfolio acquired from GlaxoSmithKline and is using free cash flow to trim its debt load in the wake of the debt-financed $660 million deal. Prestige reported Q1 net sales up 54.7%, including 4.2% organic growth in OTC health care.

You may also be interested in...

Genomma Refuses To Raise Price, Drops Prestige Bid

Genomma drops its unsolicited offer because it was unwilling to meet Prestige’s demand for a higher price. The Mexican firm said it secured funding and met other milestones Prestige insisted on.

Sales & Earnings In Brief

GlaxoSmithKline and Prestige Brands report financial results in the wake of their OTC brands deal; Allegra boosts Sanofi’s consumer business; lower private label sales hit NBTY; USANA plots North American growth.

NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building

NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts